Enveric Biosciences Inc (ENVB)

0.98 +0.05 (+5.89%) USD  |  NASDAQ  |  May 03, 16:00
0.9616 -0.02 (-1.88%) After-Hours: 20:00
More

Enveric Biosciences Research and Development Expense (Quarterly): 1.369M for Dec. 31, 2023

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 1997. Upgrade now.
Date Value
December 31, 2023 1.369M
September 30, 2023 1.352M
June 30, 2023 2.513M
March 31, 2023 1.99M
December 31, 2022 1.893M
September 30, 2022 2.056M
June 30, 2022 2.120M
March 31, 2022 1.959M
December 31, 2021 2.493M
September 30, 2021 1.219M
June 30, 2021 0.8798M
March 31, 2021 0.158M
December 31, 2020 0.0398M
September 30, 2020 0.0633M
June 30, 2020 0.051M
March 31, 2020
December 31, 2019
September 30, 2019
June 30, 2019
March 31, 2019
December 31, 2018
September 30, 2018
June 30, 2018
March 31, 2018
December 31, 2017
Date Value
September 30, 2017
June 30, 2017
March 31, 2017
December 31, 2016
September 30, 2016
June 30, 2016
March 31, 2016
September 30, 2015
June 30, 2015
March 31, 2015
December 31, 2014
September 30, 2014
June 30, 2014
March 31, 2014
December 31, 2013
September 30, 2013
June 30, 2013
March 31, 2013
December 31, 2012
September 30, 2012
June 30, 2012
March 31, 2012
December 31, 2011
September 30, 2011
June 30, 2011

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

0.0398M
Minimum
Dec 2020
2.513M
Maximum
Jun 2023
1.344M
Average
1.369M
Median
Dec 2023

Research and Development Expense (Quarterly) Benchmarks

Seelos Therapeutics Inc 5.918M
Societal CDMO Inc (DELISTED) --
Cardiff Oncology Inc 7.763M
BioVie Inc 6.470M
Adial Pharmaceuticals Inc 0.2644M